ARCHIVES

Multiple Studies Show Benefit of CTL019, A Personalized Therapy, in CLL and ALL

This article is from The Cancer Letter archive.

Vol. 36 No. 12 | December 27, 2013

Download PDF Visit The Full Archive

Related Articles

Number of Clinical R01 Applications Doubles; Funding Rate Below 20%; NCI Execs Not Satisfied

July 17, 1992

DeVita To Discuss NCI Plans for CCOPs at ACCC Meetings

January 17, 1986

DCT Advisors Approve Increased Spending On Trials Monitoring

May 6, 1994

Biomedical Science Leadership is America’s Greatest Contribution, Benno Schmidt Says

August 14, 1987

Bristol-Myers Survey Predicts Year 2000 Survival of 66%

April 3, 1987

Caribbean Conference Reports Incidence Differences With U.S.

August 22, 1986